Early radical lung cancer outcome after prompt recovery from COVID-19
infection: A real-world study
Background: There has been an increase in the number of
patients with lung cancer who had previously contracted SARS-CoV-2 and
currently require surgery. This study was to share the early
postoperative outcomes in patients who underwent radical lung cancer
surgery after early recovery of COVID-19 infection. Methods We
retrospectively collected data for 99 patients who had undergone lung
cancer surgery in our hospital during January 2022 and January 2023
(including the peak of the COVID-19 crisis）. The patients were divided
into two groups according to the inclusion criteria and exclusion
criteria. One of these included individuals with a history of SARS-CoV-2
infection. Perioperative and follow-up data at 30-day and 90-day were
recorded. Results There were no statistical differences between
groups (p > 0.05) in terms of their postoperative
complications or 30-day and 90-day postoperative readmission rates.
However, there were significant differences between groups (p
< 0.05) in terms of their tumor sizes, pathological stages,
total drainage volumes, drainage diversion times, and hospital stays.
Conclusions The results of the present trial suggested that it
is safe to implement radical curative lung cancer surgery in patients
without pulmonary impairment and in the early stages (2–4 weeks) of
recovery from SARS-CoV-2 infection.